CL2021003474A1 - Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria - Google Patents
Producto farmacéutico para terapia enzimática para tratamiento de homocistinuriaInfo
- Publication number
- CL2021003474A1 CL2021003474A1 CL2021003474A CL2021003474A CL2021003474A1 CL 2021003474 A1 CL2021003474 A1 CL 2021003474A1 CL 2021003474 A CL2021003474 A CL 2021003474A CL 2021003474 A CL2021003474 A CL 2021003474A CL 2021003474 A1 CL2021003474 A1 CL 2021003474A1
- Authority
- CL
- Chile
- Prior art keywords
- homocystinuria
- treatment
- pharmaceutical product
- enzyme therapy
- dosages
- Prior art date
Links
- 206010020365 Homocystinuria Diseases 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 title abstract 2
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 abstract 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 abstract 2
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 abstract 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962866810P | 2019-06-26 | 2019-06-26 | |
| US202062983860P | 2020-03-02 | 2020-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021003474A1 true CL2021003474A1 (es) | 2022-09-02 |
Family
ID=71670437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021003474A CL2021003474A1 (es) | 2019-06-26 | 2021-12-24 | Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria |
Country Status (24)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9675678B2 (en) | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
| DK3998067T3 (da) | 2015-11-09 | 2024-10-28 | Univ Colorado Regents | Sammensætninger og fremgangsmåder til behandling af homocystinuri |
| CA3059592A1 (en) | 2017-04-17 | 2018-10-25 | The Regents Of The University Of Colorado, A Body Corporate | Optimization of enzyme replacement therapy for treatment of homocystinuria |
| MX2021015966A (es) | 2019-06-26 | 2022-04-06 | Travere Therapeutics Switzerland Gmbh | Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria. |
| EP4025243A4 (en) * | 2019-09-03 | 2023-09-27 | Travere Therapeutics Switzerland GmbH | CYSTATHIONINE BETA-SYNTHASE ENZYMA THERAPY FOR THE TREATMENT OF HIGH HOMOCYSTEINE LEVELS |
| CN115721735A (zh) * | 2022-10-13 | 2023-03-03 | 呈诺再生医学科技(北京)有限公司 | Cbs基因在制备糖尿病视网膜病变治疗药物中的应用 |
| CN115671059B (zh) * | 2022-11-17 | 2024-06-11 | 兆科药业（合肥）有限公司 | 一种盐酸氨酮戊酸冻干制剂及制备方法 |
| CN120610012A (zh) * | 2023-10-20 | 2025-09-09 | T&D诊断加拿大私人有限公司 | 用于诊断个体整体健康状况的标志物以及装置 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656425A (en) | 1993-08-17 | 1997-08-12 | Regents Of The University Of Colorado | Screening for mutations by expressing cDNA segments |
| US5523225A (en) | 1993-09-13 | 1996-06-04 | Regents Of The University Of Colorado | DNA sequence encoding human cystathionine β-synthase |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5635375A (en) | 1995-01-09 | 1997-06-03 | Regents Of The University Of Colorado | Method of increasing the yield and heme saturation of cystathione β-synthase |
| US6653062B1 (en) | 2000-07-26 | 2003-11-25 | Wisconsin Alumni Research Foundation | Preservation and storage medium for biological materials |
| WO2003106971A2 (en) | 2002-06-17 | 2003-12-24 | The Regents Of The University Of Colorado | HUMAN CYSTATHIONINE β-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF |
| EP1396537A1 (en) | 2002-09-04 | 2004-03-10 | Avidis SA | Treatment of elevated plasma homocysteine |
| CA2534995A1 (en) | 2003-07-31 | 2005-05-19 | Anticancer, Inc. | The use of plp with peg-rmetase in vivo for enhanced efficacy |
| US20070010492A1 (en) | 2005-07-11 | 2007-01-11 | Generale Robert J | Composition and method for reducing homocysteine caused by drugs containing methyl compounds |
| CA2771575A1 (en) | 2009-08-29 | 2011-03-03 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| EP2510100B1 (en) * | 2009-12-09 | 2017-10-11 | CureVac AG | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| BR112013000027A2 (pt) | 2010-07-01 | 2017-07-11 | Isis Innovation | tratamento de distúrbios cognitivos |
| US9034318B2 (en) * | 2011-08-30 | 2015-05-19 | The Regents Of The University Of Colorado, A Body Corporate | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
| US9243239B2 (en) | 2012-03-26 | 2016-01-26 | The Regents Of The University Of Colorado, A Body Corporate | Purification of cystathionine beta-synthase |
| US9675678B2 (en) | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
| WO2015033279A1 (en) | 2013-09-04 | 2015-03-12 | Mahesh Kandula | Compositions and methods for the treatment of homocystinuria |
| BR112016011195A2 (pt) | 2013-11-18 | 2017-09-19 | Rubius Therapeutics Inc | Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico |
| CN106456744A (zh) | 2014-04-01 | 2017-02-22 | 鲁比厄斯治疗法股份有限公司 | 用于免疫调节的方法和组合物 |
| WO2016183482A1 (en) | 2015-05-13 | 2016-11-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| DK3998067T3 (da) * | 2015-11-09 | 2024-10-28 | Univ Colorado Regents | Sammensætninger og fremgangsmåder til behandling af homocystinuri |
| MX2019000205A (es) | 2016-07-07 | 2019-09-23 | Rubius Therapeutics Inc | Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno. |
| CA3059592A1 (en) | 2017-04-17 | 2018-10-25 | The Regents Of The University Of Colorado, A Body Corporate | Optimization of enzyme replacement therapy for treatment of homocystinuria |
| MX2021015966A (es) | 2019-06-26 | 2022-04-06 | Travere Therapeutics Switzerland Gmbh | Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria. |
| EP4025243A4 (en) * | 2019-09-03 | 2023-09-27 | Travere Therapeutics Switzerland GmbH | CYSTATHIONINE BETA-SYNTHASE ENZYMA THERAPY FOR THE TREATMENT OF HIGH HOMOCYSTEINE LEVELS |
-
2020
- 2020-06-26 MX MX2021015966A patent/MX2021015966A/es unknown
- 2020-06-26 EP EP20743019.0A patent/EP3990005B1/en active Active
- 2020-06-26 PT PT207430190T patent/PT3990005T/pt unknown
- 2020-06-26 AU AU2020302079A patent/AU2020302079A1/en not_active Abandoned
- 2020-06-26 SI SI202030699T patent/SI3990005T1/sl unknown
- 2020-06-26 ES ES20743019T patent/ES3058596T3/es active Active
- 2020-06-26 JP JP2021576921A patent/JP2022539077A/ja active Pending
- 2020-06-26 CN CN202080060487.6A patent/CN114786712A/zh active Pending
- 2020-06-26 CA CA3145426A patent/CA3145426A1/en active Pending
- 2020-06-26 PL PL20743019.0T patent/PL3990005T3/pl unknown
- 2020-06-26 FI FIEP20743019.0T patent/FI3990005T3/fi active
- 2020-06-26 DK DK20743019.0T patent/DK3990005T3/da active
- 2020-06-26 RS RS20251214A patent/RS67521B1/sr unknown
- 2020-06-26 PH PH1/2021/553235A patent/PH12021553235A1/en unknown
- 2020-06-26 EP EP25198152.8A patent/EP4663239A3/en active Pending
- 2020-06-26 SM SM20260042T patent/SMT202600042T1/it unknown
- 2020-06-26 HR HRP20251579TT patent/HRP20251579T1/hr unknown
- 2020-06-26 WO PCT/US2020/039870 patent/WO2020264333A1/en not_active Ceased
- 2020-06-26 KR KR1020227002804A patent/KR20220044726A/ko active Pending
- 2020-06-26 US US17/622,112 patent/US12364765B2/en active Active
- 2020-06-26 LT LTEPPCT/US2020/039870T patent/LT3990005T/lt unknown
- 2020-06-26 IL IL289245A patent/IL289245B2/en unknown
- 2020-06-26 BR BR112021026292A patent/BR112021026292A2/pt unknown
-
2021
- 2021-12-16 MX MX2026001319A patent/MX2026001319A/es unknown
- 2021-12-23 SA SA521431197A patent/SA521431197B1/ar unknown
- 2021-12-24 CL CL2021003474A patent/CL2021003474A1/es unknown
-
2025
- 2025-06-04 JP JP2025093526A patent/JP2025143275A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12364765B2 (en) | 2025-07-22 |
| EP3990005B1 (en) | 2025-08-27 |
| MX2026001319A (es) | 2026-03-02 |
| ES3058596T3 (en) | 2026-03-11 |
| EP3990005A1 (en) | 2022-05-04 |
| BR112021026292A2 (pt) | 2022-05-31 |
| US20220265835A1 (en) | 2022-08-25 |
| JP2025143275A (ja) | 2025-10-01 |
| HRP20251579T1 (hr) | 2026-01-30 |
| FI3990005T3 (fi) | 2025-11-28 |
| KR20220044726A (ko) | 2022-04-11 |
| CA3145426A1 (en) | 2020-12-30 |
| PL3990005T4 (pl) | 2026-03-02 |
| SI3990005T1 (sl) | 2026-02-27 |
| SMT202600042T1 (it) | 2026-03-09 |
| WO2020264333A1 (en) | 2020-12-30 |
| DK3990005T3 (da) | 2025-12-08 |
| SA521431197B1 (ar) | 2024-12-03 |
| IL289245A (en) | 2022-02-01 |
| PL3990005T3 (pl) | 2026-03-02 |
| MX2021015966A (es) | 2022-04-06 |
| LT3990005T (lt) | 2026-01-12 |
| PH12021553235A1 (en) | 2022-08-22 |
| EP4663239A2 (en) | 2025-12-17 |
| AU2020302079A1 (en) | 2022-02-17 |
| IL289245B2 (en) | 2025-09-01 |
| PT3990005T (pt) | 2025-12-17 |
| IL289245B1 (en) | 2025-05-01 |
| EP4663239A3 (en) | 2026-03-11 |
| CN114786712A (zh) | 2022-07-22 |
| RS67521B1 (sr) | 2026-01-30 |
| JP2022539077A (ja) | 2022-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521431197B1 (ar) | منتج دوائي للعلاج بالإنزيم لعلاج البيلة الهوموسيستينية (اضطراب في الهوموسيستين) | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| CO6280475A2 (es) | Metodo para tratar la deficiencia de vitamina b12 | |
| MY197423A (en) | Recombinant herpes simplex virus and use thereof | |
| CY1117995T1 (el) | Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις | |
| AR050418A1 (es) | Dosificacion fija de anticuerpos her | |
| MX2016010179A (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| EA201591701A1 (ru) | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv | |
| ZA201901370B (en) | Formulations for oral administration of active agents | |
| AR112166A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de hepatitis b | |
| MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. | |
| EP3501532A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
| DOP2024000016A (es) | Proteínas actrii y usos de las mismas | |
| AR037496A1 (es) | Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables | |
| EA201992142A1 (ru) | Фармацевтические композиции и их применения | |
| MX2022003628A (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente. | |
| MX2023013301A (es) | Una pluralidad de particulas tasquinimod y su uso. | |
| CL2022000095A1 (es) | Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad | |
| MX2018013428A (es) | Composicion farmaceutica de comprimido en comprimido que comprende ciclofosfamida y capecitabina. | |
| MX2019014166A (es) | Composicion farmaceutica de caseinato de sodio y antineoplasicos para el tratamiento de cancer. | |
| MX2026002765A (es) | Formulaciones de proteinas de fusion de igf2 y usos terapeuticos de las mismas | |
| AR120453A1 (es) | Combinación de un inhibidor de btk y un inhibidor de mdm2 para el tratamiento del cáncer | |
| MX2024001154A (es) | Tratamiento del eczema de manos con baricitinib. | |
| ZA202102913B (en) | Dosage regime |